Healthcare shares are flat in pre-market trade.
Shares of Rosetta Genomics (
) are up 35% at $4.29 pre-market after the company said it has
signed a master service provider agreement with an undisclosed
"major global biopharmaceutical company," under which Rosetta will
provide its microRNA profiling and other services pursuant to a
collaboration in important areas of unmet medical need utilizing a
novel therapeutic approach.
And, Biopharmaceutical company Cubist Pharmaceuticals (
) reported that its total net revenues for Q4 were $299.7 million,
including DIFICID revenues since the completion of CBST's
acquisition of Optimer Pharmaceuticals, Inc. on Oct. 24, 2013. This
is up 22% compared to $245.9 million in Q4 2012. Analysts are
expecting Q4 revenues of $280.82 million, if comparable.
For FY13, the company expects to report net revenues of $1.1
billion, up 14% compared to $926.4 million in 2012. Analysts are
looking for revenues of $1.03 billion.
Cell Therapeutics (
) is 13% higher this morning after it said it has reached an
agreement with Novartis to reacquire rights to two anti-cancer
compounds -- pixantrone (PIXUVRI) and paclitaxel poliglumex
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.